| Title: | Hypothesis-free evaluation of circulating metabolome provides cell-specific insights regarding the role of energy substrate availability in amyotrophic lateral sclerosis |
| Journal: | BMC Medicine |
| Published: | 6 Mar 2026 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/41787388/ |
| DOI: | https://doi.org/10.1186/s12916-026-04727-w |
| URL: | http://dx.doi.org/10.1186/s12916-026-04727-w |
Publication 17485
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with limited therapeutic options. The circulating metabolome comprises small molecules present in plasma/serum which are the intermediates and end-products of cellular metabolism, and is linked to ALS pathogenesis.MethodsWe conducted hypothesis-free two-sample Mendelian randomisation (MR) analysis of the concentration of 575 plasma/serum metabolites, to determine which are causally linked to risk of ALS. Significant metabolites were validated in an independent GWAS of plasma/serum metabolite concentrations and evaluated for sex-specific effects. Correlations between directly measured patient biofluid metabolite concentrations and ALS risk/severity were examined in 94 ALS patients and 40 controls. We experimentally assessed metabolic function in a murine neurons and human astrocytes carrying an ALS-associated G4C2-repeat expansion within C9orf72.ResultsMR causally associated five metabolites with ALS risk after multiple-testing correction. Higher serum concentration of glycoprotein acetyls (P = 9.7e − 9, β = 0.21) and the peptide DSGEGDFXAEGGGVR (P = 8.0e − 6, β = 0.22) was associated with increased ALS risk, whereas higher plasma concentration of phenylalanylserine, isobutyrylcarnitine, and acetylcarnitine was protective (P < 5e − 5, β = − 0.29 to − 0.72). DSGEGDFXAEGGGVR has been linked to glucose metabolism but we have used genetic fine-mapping to link DSGEGDFXAEGGGVR, neuronal glucose uptake through GLUT3, and ALS risk. Direct measurement of metabolite concentrations in patient biofluids revealed elevated acetylcarnitine levels in patients with ALS, which were associated with delayed symptom onset (Cox regression, P = 0.02, HR = 0.4). Similarly, lactate is elevated in ALS patient CSF (ANOVA, P = 1.3e − 3) and in patients with longer survival time (Cox regression, P = 0.03, HR = 0.3). Plasma fructose is elevated in ALS patients with shorter survival time (Cox regression, P = 0.02, HR = 1.1). In vitro, neurons and astrocytes carrying an ALS-associated G4C2-repeat expansion within C9orf72 demonstrated reduced metabolic flexibility.ConclusionsWe provide evidence that impaired energy substrate availability contributes to ALS risk and severity. CNS cell types differ in their use of energy substrates and therefore we postulate the relative importance of different cell types for different stages of disease. Our findings support further investigation of metabolic interventions to treat or prevent ALS.</p>
21 Authors
- Elham Alhathli
- Johnathan Cooper-Knock
- Zain-Ul-Abideen Girach
- Thomas H. Julian
- Claudia Bauer
- Hannah O. Timmons
- Billie D. Ward
- Heather Walker
- Mimoun Azzouz
- Mohamed A. Elrayess
- Fatima Al-Khelaifi
- Noha A. Yousri
- Aytac Gul
- Alan Kelsall
- Tobias Moll
- Calum Harvey
- Sarah Gornall
- Kari Wong
- Scott P. Allen
- Andrew Strange
- Pamela J. Shaw
1 Application
| Application ID | Title |
|---|---|
| 68812 | Investigating environmental risk factors for ALS and FTD using mendelian randomisation |
Enabling scientific discoveries that improve human health